Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
Nov 20, 2026, 17:19

Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop

Paris Margaritis, Chief Scientific Officer at GeneVentiv Therapeutics, Inc, shared a post on LinkedIn:

“It was a pleasure and an honor to participate in the World Federation of Hemophilia Workshop on New Technology and Gene Therapy in Montréal, Canada.

I was delighted to present GeneVentiv Therapeutics recent preclinical work on GENV-HEM, an AAV-based gene therapy approach expressing FVa for hemophilia A, with or without FVIII inhibitors.

It was a wonderful opportunity to exchange ideas and engage in stimulating scientific discussions, particularly during the panel discussion. It was also great to reconnect with colleagues and friends who share a commitment to advancing therapies for people living with bleeding disorders.

Many thanks to the World Federation of Hemophilia and the Program Committee for the invitation and for putting together such an engaging and productive meeting.”

Paris Margaritis

Stay updated with Hemostasis Today.